Design, synthesis, and enzymatic characterization of quinazoline-based CYP1A2 inhibitors
Graphical abstract
Section snippets
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
The work was part-funded by R01CA193286 (CX), College of Pharmacy Frank Duckworth Endowment (CX), and University of Florida Health Cancer Center Startup fund (CX).
References (13)
- National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health....
- Hu SS. Tobacco product use among adults—United States, 2013–2014. MMWR Morbidity and Mortality Weekly Report....
- Group UCSW. US Cancer Statistics Data Visualizations Tool, based on November 2017 submission data (1999–2015): US...
- et al.
Understanding tobacco smoke carcinogen NNK and lung tumorigenesis
Int J Oncol
(2006) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines
Chem Res Toxicol
(1998)- et al.
Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate
Drug Metab Dispos
(2001)
There are more references available in the full text version of this article.
Cited by (7)
Synthesis and Structure-Photophysics Evaluation of 2-N-Amino-quinazolines: Small Molecule Fluorophores for Solution and Solid State
2021, Chemistry - An Asian JournalBiological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes
2021, Archives of Pharmacal Research
© 2019 Elsevier Ltd. All rights reserved.